18 results about "Organ system" patented technology

Systems and methods for designing and generating architectures for the selective transport across fluid networks in 3D printed organ systems are provided. An example method includes: identifying, two or more fluid networks of a reference organ system and a transport characteristic between the two or more fluid networks; generating a model of each fluid network that includes channel parameters for channels associated with the fluid network; determining, based on the transport characteristic, a wall thickness between a channel of one fluid network, to a channel of another fluid network, for each of the two or more fluid networks; integrating the models of each fluid network to generate an organ system model that includes at least a representation of the functional region based on the wall thicknesses between respective channels between the two or more fluid networks; and generating a 3D printed organ system based on the organ system model.

A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter / enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and / or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.

The invention discloses a multi-organ system biological age assessment method, and relates to the technical field of health assessment, and the method comprises the steps: S1, obtaining data; step S2, preprocessing the data; s3, screening biological age construction indexes of the multi-organ system; and S4, estimating the biological age of the multi-organ system. According to the method, the defects of an existing biological age model in the aspects of crowd applicability and prediction accuracy are overcome, accurate evaluation of the biological age of a multi-organ system is achieved, early recognition and accurate prevention and control of senescence-related diseases can be achieved, systematicness and heterogeneity of the senescence process are revealed, and the method is suitable for popularization and application. And more evidences are provided for pertinently intervening the senescence process.

This invention relates to the field of biomedical technology, specifically disclosing a modular interactive organ-on-a-chip and its application method. The chip body includes an inlet and an outlet, a flow channel at the bottom of the chip body connecting the inlet and outlet, multiple chambers on the chip body, an endothelial barrier installed within each chamber, and an organoid culture device. The bottoms of the multiple chambers are connected to the flow channel. The inlet, outlet, and chambers form a dynamic circulation system. This invention effectively achieves physiological coupling between organs, establishing bidirectional feedback regulation between organs; it also supports the large-scale expansion of multiple culture chambers to form more complex multi-organ networks; it enables the construction of a cross-chip microphysiological communication network covering multiple human systems; and by achieving cross-scale parameter monitoring from molecular transport to organ function, it provides highly scalable and efficient measurement capabilities for pathophysiological research of complex multi-organ systems and high-throughput drug screening.

Systems and methods for selectively perfusing cadaverous organ systems for surgical simulation are provided. A first fluid reservoir contains a first perfusion fluid and fluidically connects to conduit, which fluidically connects to a first body part associated with the organ system. A pump fluidically connects to the first reservoir and conduit and directs the first perfusion fluid into the first body part. A second fluid reservoir contains a second perfusion fluid and fluidically connects to conduit, which fluidically connects to a second body part associated with the organ system. In aspects, the second fluid reservoir is positioned at higher elevation than the organ system to create passive feed pressure of the second perfusion fluid to the second body part. The systems may include drainage mechanisms from the organ system. Aspects include selective perfusion of the liver, thorax, head and neck, and / or extremities of a cadaver.

The application provides a drug circulation simulation method based on a digital organ system, pre-stored organ lesion states are input as initial conditions D(0) into the digital organ system, circulation flow resistance and drug transmembrane resistance in the digital organ system are adjusted during perfusion, so that organ lesion trends D(t) show a nonlinear downward trend over time, the circulation flow resistance and the drug transmembrane resistance are respectively fluid mechanics parameters and drug transport parameters in the digital organ system; the fluid dynamics behavior of the digital organ simulation system is quantitatively described by a flow resistance system, the flow resistance system couples macroscopic structures at the inlet of perfusion blood vessels and microscopic structures of end-liver lobule functional units through unified flow resistance physical parameters, and is used for organ cross-scale structure modeling calculation; the liver lobule functional unit is simulated through a porous medium model, and the liver lobule functional unit is equivalent to a calculable unit with specific fluid mechanics characteristics.

The present invention relates to the process of using signal-emitting and / or receiving objects or smart medical devices for image acquisition, and which can utilize a variety of external energy sources which are directly applied and / or incorporated into the host subject to produce a continuous and dynamic visual representation of the host subject on a computer display, which representation hereafter will be referred to as a visualization map. The derived images can be targeted, to small (i.e., focal) areas of clinical interest, to organ systems, or the entire body. The present invention provides a scalable method for continuous and dynamic imaging over prolonged periods of time, as dictated by the clinical context.

The present invention relates to methods for producing an artificial basement membrane comprising a fiber mesh, artificial basement membranes comprising a fiber mesh, in particular produced by means of the method according to the invention, as well as in vitro test systems, cell culture systems, filtration systems and organ systems comprising at least one artificial basement membrane of the present invention.

This invention discloses a method and device for predicting disease risk based on plasma proteomics and waist circumference, belonging to the field of medical data processing. Utilizing 2,920 plasma proteins from 52,879 participants in the UK Biobank, this invention constructs a proteomics-based waist circumference proWC score using LASSO regression, and derives the protein-anthropometric difference index proWCΔ to quantify the difference between proteomics-based waist circumference and measured waist circumference. Based on the proWC score and proWCΔ, disease risk association analysis, mortality prediction, causal mediation analysis, and dietary association analysis were conducted across 14 organ systems, demonstrating that proWC has superior clinical predictive value compared to waist circumference alone. Furthermore, based on proWC, a hidden high-risk subgroup was identified—patients with normal measured waist circumference but a near-overtly obese risk of diabetes-related death. By constructing proWCΔ and proWC, this invention elevates the assessment of central obesity from morphological measurements to the molecular level, providing a new molecular framework for precise risk stratification of central obesity.

A system and method for interactive three-dimensional visualization of physiological stress effects on the human body uses biomarker correlation algorithms to determine physiological responses to physical trauma and toxic stress events. The system receives stress event data, calculates biomarker levels including cortisol, blood pressure, blood sugar, and inflammatory markers, and identifies affected organ systems including cardiovascular, nervous, endocrine, digestive, immune, and reproductive systems. Three-dimensional anatomical models are modified with visual characteristics depicting stress-induced changes based on the biomarker data, including color alterations, geometric deformations, and animated effects. A temporal progression interface enables visualization of immediate, short-term, and long-term physiological effects. Spatial audio synchronized with visual animations provides immersive auditory feedback. Cross-platform rendering modules optimize visualization for mobile devices, desktop computers, tablets, virtual reality headsets, and augmented reality glasses. The system provides for real-time interactive manipulation of anatomical visualizations, particularly for pediatric toxic stress education related to corporal punishment.

The invention discloses a comprehensive analysis system for medical health data, and the method comprises the following steps: extracting multi-dimensional clinical features from the medical health data, calculating a K theoretical index and a Cheesimons invariant, and obtaining a health topology spectrum index; on the basis of the topological spectrum index and continuous physiological monitoring, calculating the variation derivative of the Bennacadokr action quantity, and generating a causal structure collapse index in combination with Hessian matrix spectrum distribution; calculating a holographic critical dimension index in combination with the collapse index and the organ system score data; constructing a hypersymmetric theoretical framework according to the dimension index and clinical intervention historical data, and generating a topology protection intervention index; and fusing the intervention index with patient and environment multi-dimensional constraints, establishing ternary system function mapping under a high-order category theory framework, and calculating topology decision invariants. The accuracy of the medical intervention strategy is improved by analyzing the medical health data.

The current document is directed to an automated system that continuously collects and processes physiological, functional, and health data, processes the collected data to continuously develop and refine computational models that generate, from the collected data, multiple health-entropy metrics for the individual's whole-body, for specific-organ-systems, for specific multi-organ-system conditions, and for specific functionalities. The health-entropy metrics are transmitted to organizations, professionals, and individuals for monitoring individuals' health, for diagnosing diseases and conditions, for developing therapies and treatments for individuals as well as generally applicable therapies and treatments, for supporting basic research in pharmaceutical development, biomarker selection, diagnosing and monitoring various diseases and conditions, and public health monitoring, and for use by individuals for diet planning, accessing healthcare services, making lifestyle selections and adjustments, and monitoring therapies and treatments.

Provided here are cell culture system with tunable stiffness comprising a biocompatible polydimethyl siloxane substrate and a polyelectrolyte multilayer. Also provided here are methods of making and using these systems as research and / or product development models for different tissue and organ systems.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, methods for use of such compositions in treating, preventing, ameliorating, curing and / or diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly nervous system diseases, disorders and injuries and cardiovascular system diseases, disorders and injuries. The invention also provides the use of such compositions in treating, preventing, ameliorating, curing and / or diagnosing diseases, disorders and conditions in a variety of other tissues, organs and organ systems. The invention also provides medical devices comprising one or more such compositions of the invention.

The present invention is in the field of pharmaceutical chemistry, biotechnology and pharmacy. The present invention provides compositions comprising one or more collagen-mimetic peptides, optionally linked to one or more therapeutic compounds or one or more imaging compounds; methods for using such compositions for the treatment, prevention, amelioration, cure and / or diagnosis of certain diseases and physical disorders of humans and veterinary animals, in particular diseases, disorders and injuries of the nervous system and of the cardiovascular system. The present invention also provides the use of such compositions in the treatment, prevention, amelioration, cure and / or diagnosis of a variety of other diseases, disorders and conditions in tissues, organs and organ systems. The present invention also provides medical devices comprising one or more such compositions of the present invention.

The invention belongs to the technical field of medical nutrition management, and particularly relates to a nutrition intake difference value analysis and quantitative matching system under a complex chronic common disease scene, which comprises a common disease nutrition demand knowledge base module, a common disease nutrition demand knowledge base module, a common disease nutrition demand knowledge base module, a common disease nutrition demand knowledge base module, a common disease nutrition demand knowledge base module and a common disease nutrition demand knowledge base module, setting a nutritional requirement priority; and the medicine-nutrition interaction adaptation module is used for generating a final nutrition constraint which overlaps the medicine influence by integrating a clinical chronic disease medicine database, automatically synchronizing a medicine use record of a patient, identifying a taboo nutrient corresponding to a medicine and recommending a collaborative nutrient, and performing risk early warning and replacement recommendation on a conflict scheme. The co-disease classification system is constructed according to the organ system and the disease severity, and the multi-dimensional nutrition constraint rule is matched for each type of co-diseases, so that the multi-dimensional nutrition constraint accurate adaptation in a complex co-disease scene is realized, and the limitation of nutrition management of a single disease is broken through.

Implementations of a microphysiological system may include at least one first inlet for receiving a fluid medium; a fat module including adipocytes, the fat module configured to receive the fluid medium; a liver module including hepatocytes; a channel between the fat module and the liver module, the channel configured to promote communication of the fluid medium from the fat module to the liver module; and the channel configured for exchange of one or more of nutrients, signaling molecules, and drugs between the fat module and the liver module.

This invention provides a method for minimizing adverse effects mediated by external influences on cells, tissues, organ systems, and living organisms. [Solution] A method is provided for treating with an effective amount of a graft or block copolymer having cationic, hydrophobic, or anionic sites and hydrophilic inactivation sites. The copolymer is PLL-g-PEG. The copolymer exhibits bioadhesion through electrostatic and hydrophobic interactions, as well as inactivation by the hydrophilic sites. The copolymer is useful for reducing the viral infection rate of target cells and reducing host morbidity. The copolymer is useful for reducing toxicity associated with ADCs, including corneal epithelial toxicity. Formulations of the copolymer are safe and well tolerable. Usefulness and benefits can be obtained by treating epithelial cells and surfaces, including precursor or stem cell corneal epithelial cells, with the copolymer.